Precigen Inc (PGEN)

$4.55 +0.37 (8.85%)
Market Cap 1.51B
Revenue (ttm) 3.93M
Net Income (ttm) -126.24M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -3,212.21%
Debt to Equity Ratio 2.22
Volume 3,928,700
Avg Vol 4,564,902
Day's Range N/A - N/A
Shares Out 353.83M
Stochastic %K 97%
Beta 1.10
Analysts Sell
Price Target $8.50

Company Profile

Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine an...

Industry: Biotechnology
Sector: Healthcare
Phone: 301 556 9900
Address:
20374 Seneca Meadows Parkway, Germantown, United States
Inoboatguy
Inoboatguy Jan. 6 at 11:31 PM
$INO $PGEN is dog turd crap 💩 Scope surgery still needed during treatment, not counted in trial Pgen is 💩 INO is the far superior treatment 💪 winner
4 · Reply
M22
M22 Jan. 6 at 9:55 PM
$PGEN https://www.openpr.com/news/4334898/immunotherapy-drugs-market-to-reach-usd-872-64-billion-by-2033
0 · Reply
M22
M22 Jan. 6 at 9:48 PM
$PGEN https://www.bcbst.com/UpcomingMPs/Topics_12_31_25/Zopapogene%20Imadenovec-drba%20(Papzimeos)_pol.pdf
1 · Reply
M22
M22 Jan. 6 at 9:44 PM
$PGEN words getting out https://www.wdef.com/new-option-for-rare-hpv-disease/
0 · Reply
JFDI
JFDI Jan. 6 at 8:58 PM
$PGEN so sexy
0 · Reply
Champi2305
Champi2305 Jan. 6 at 8:10 PM
$PGEN
0 · Reply
INOVIO
INOVIO Jan. 6 at 7:47 PM
$INO $PGEN @iBio_GlaisterPIT One question before I answer you. Hypothetically, when INOVIO’s BLA for 3107 is FDA approved in ~10 months, what is the real difference between INOVIO at a ~$100M market cap and Precigen at ~$1.5B? Other than the medicines being different and patients having a choice, both would have FDA approval, correct? Do you think investors would look at INOVIO and say it’s massively undervalued or look at Precigen and ask why it’s valued 15X higher? This is a hypothetical question if they get their FDA approval. Please don’t respond with “FDA won’t approve it.” We’ve all heard that argument before.
1 · Reply
ivanhoff
ivanhoff Jan. 6 at 6:48 PM
$PGEN - speculative biotech with no profit and a tiny revenue, potentially setting up in a high-tight-flag setup.
0 · Reply
Champi2305
Champi2305 Jan. 6 at 6:41 PM
$PGEN $4,5 then $5
0 · Reply
iBio_GlaisterPIT
iBio_GlaisterPIT Jan. 6 at 6:11 PM
$INO $PGEN Some paid Inovio employees are trying to convince you the math that, as long as Precigen continues to rise, it’s somehow good for Inovio’s investors. My question is what math is that? It’s not mathematics as humans know it, so where does that math come from? Let’s look at JUST TODAY’S FACTS ALONE: Precigen - UP over 7% Inovio - Once again, down. Today only 2.5% Please do explain this Unicorn to us feeble-minded folks! Explain it like we only know 1+1=2. But give me a minute, going to make some popcorn, put on my hip-waders and put on my face shield so I don’t get splattered with how deep this shit’s gonna get!
1 · Reply
Latest News on PGEN
Precigen to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 4:05 PM EST - 1 day ago

Precigen to Present at the 44th Annual J.P. Morgan Healthcare Conference

Precigen Is Still A Buy After The Papzimeos Rally

Nov 25, 2025, 6:51 AM EST - 6 weeks ago

Precigen Is Still A Buy After The Papzimeos Rally

Precigen, Inc. (PGEN) Q3 2025 Earnings Call Transcript

Nov 13, 2025, 10:51 PM EST - 7 weeks ago

Precigen, Inc. (PGEN) Q3 2025 Earnings Call Transcript

Precigen Reports Third Quarter 2025 Financial Results and Business Updates

Nov 13, 2025, 4:05 PM EST - 7 weeks ago

Precigen Reports Third Quarter 2025 Financial Results and Business Updates

Precigen to Announce Third Quarter 2025 Financial Results and Provide Business Updates on November 13

Nov 6, 2025, 4:30 PM EST - 2 months ago

Precigen to Announce Third Quarter 2025 Financial Results and Provide Business Updates on November 13

Precigen Announces Long-Term Follow-Up Results Highlighting Ongoing Durable Complete Responses after Treatment with PAPZIMEOS, the First and Only FDA-approved Therapy for Adults with Recurrent Respiratory Papillomatosis

Oct 13, 2025, 7:00 AM EDT - 3 months ago

Precigen Announces Long-Term Follow-Up Results Highlighting Ongoing Durable Complete Responses after Treatment with PAPZIMEOS, the First and Only FDA-approved Therapy for Adults with Recurrent Respiratory Papillomatosis

Precigen Announces Up to $125 Million Non-Dilutive Financing

Sep 3, 2025, 7:00 AM EDT - 4 months ago

Precigen Announces Up to $125 Million Non-Dilutive Financing

Precigen, Inc. - Special Call

Sep 2, 2025, 1:55 PM EDT - 4 months ago

Precigen, Inc. - Special Call

Precigen to Participate in Upcoming Virtual Fireside Chats Hosted by Cantor and H.C. Wainwright

Aug 25, 2025, 8:05 AM EDT - 4 months ago

Precigen to Participate in Upcoming Virtual Fireside Chats Hosted by Cantor and H.C. Wainwright

Undercovered Dozen: Precigen, ONEOK, Bitmine And More

Aug 22, 2025, 10:43 AM EDT - 4 months ago

Undercovered Dozen: Precigen, ONEOK, Bitmine And More

BMNR OKE

Precigen: This Billion-Dollar Approval Is Still Undervalued

Aug 15, 2025, 3:15 PM EDT - 5 months ago

Precigen: This Billion-Dollar Approval Is Still Undervalued

Why Is Precigen Stock Surging On Friday?

Aug 15, 2025, 9:48 AM EDT - 5 months ago

Why Is Precigen Stock Surging On Friday?

US FDA approves Precigen's immunotherapy for rare respiratory disease

Aug 15, 2025, 7:18 AM EDT - 5 months ago

US FDA approves Precigen's immunotherapy for rare respiratory disease

Precigen Announces Full FDA Approval of PAPZIMEOS (zopapogene imadenovec-drba), the First and Only Approved Therapy for the Treatment of Adults with Recurrent Respiratory Papillomatosis

Aug 15, 2025, 7:00 AM EDT - 5 months ago

Precigen Announces Full FDA Approval of PAPZIMEOS (zopapogene imadenovec-drba), the First and Only Approved Therapy for the Treatment of Adults with Recurrent Respiratory Papillomatosis

Precigen: August Is Pivotal For This Biotech Innovator

Jul 7, 2025, 5:58 PM EDT - 6 months ago

Precigen: August Is Pivotal For This Biotech Innovator

Precigen Reports First Quarter 2025 Financial Results and Business Updates

May 14, 2025, 4:05 PM EDT - 8 months ago

Precigen Reports First Quarter 2025 Financial Results and Business Updates

Precigen and Recurrent Respiratory Papillomatosis Foundation to Host the 2025 International RRP Awareness Day on June 11th

Apr 16, 2025, 8:05 AM EDT - 9 months ago

Precigen and Recurrent Respiratory Papillomatosis Foundation to Host the 2025 International RRP Awareness Day on June 11th

Precigen, Inc. (PGEN) Q4 2024 Earnings Call Transcript

Mar 19, 2025, 7:47 PM EDT - 10 months ago

Precigen, Inc. (PGEN) Q4 2024 Earnings Call Transcript

Precigen Reports Full Year 2024 Financial Results and Business Updates

Mar 19, 2025, 4:05 PM EDT - 10 months ago

Precigen Reports Full Year 2024 Financial Results and Business Updates

Precigen to Announce Full Year 2024 Financial Results and Provide Business Updates on March 19th

Mar 13, 2025, 8:05 AM EDT - 10 months ago

Precigen to Announce Full Year 2024 Financial Results and Provide Business Updates on March 19th

Precigen: UltraCAR-T Development Brings Another Side Of Pipeline Advancement

Feb 28, 2025, 8:56 AM EST - 11 months ago

Precigen: UltraCAR-T Development Brings Another Side Of Pipeline Advancement

FDA Grants Priority Review to Precigen's BLA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis with PDUFA Target Action Date Set for August 27, 2025

Feb 25, 2025, 8:05 AM EST - 11 months ago

FDA Grants Priority Review to Precigen's BLA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis with PDUFA Target Action Date Set for August 27, 2025

Precigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 13, 2025, 7:00 AM EST - 1 year ago

Precigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at the 43rd Annual J.P. Morgan Healthcare Conference

Precigen to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 9, 2025, 8:30 AM EST - 1 year ago

Precigen to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Precigen Completes Submission of BLA with Request for Priority Review to the FDA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis

Dec 30, 2024, 7:00 AM EST - 1 year ago

Precigen Completes Submission of BLA with Request for Priority Review to the FDA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis

Precigen Announces $79.0 Million Private Placement Offering of Convertible Preferred Stock

Dec 27, 2024, 9:00 AM EST - 1 year ago

Precigen Announces $79.0 Million Private Placement Offering of Convertible Preferred Stock

Precigen Reports Third Quarter 2024 Financial Results and Business Updates

Nov 14, 2024, 4:30 PM EST - 1 year ago

Precigen Reports Third Quarter 2024 Financial Results and Business Updates

Precigen to Participate in the Stifel 2024 Healthcare Conference

Nov 12, 2024, 4:05 PM EST - 1 year ago

Precigen to Participate in the Stifel 2024 Healthcare Conference

Precigen to Participate in the 2024 Cantor Global Healthcare Conference

Sep 16, 2024, 4:30 PM EDT - 1 year ago

Precigen to Participate in the 2024 Cantor Global Healthcare Conference

Titan Machinery Reports Weak Preliminary Results, Joins Precigen, Gogoro And Other Big Stocks Moving Lower In Thursday Pre-Market Session

Aug 15, 2024, 8:11 AM EDT - 1 year ago

Titan Machinery Reports Weak Preliminary Results, Joins Precigen, Gogoro And Other Big Stocks Moving Lower In Thursday Pre-Market Session

GGR TITN

Precigen, Inc. (PGEN) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 7:03 PM EDT - 1 year ago

Precigen, Inc. (PGEN) Q2 2024 Earnings Call Transcript

Precigen Reports Second Quarter and First Half 2024 Financial Results and Business Updates

Aug 14, 2024, 4:05 PM EDT - 1 year ago

Precigen Reports Second Quarter and First Half 2024 Financial Results and Business Updates

Precigen to Announce Second Quarter and First Half 2024 Financial Results on August 14th

Aug 9, 2024, 8:00 AM EDT - 1 year ago

Precigen to Announce Second Quarter and First Half 2024 Financial Results on August 14th

Precigen Announces Pricing of $30.0 Million Public Offering of Common Stock

Aug 7, 2024, 9:30 PM EDT - 1 year ago

Precigen Announces Pricing of $30.0 Million Public Offering of Common Stock

Precigen Announces Proposed $30 Million Public Offering of Common Stock

Aug 6, 2024, 4:04 PM EDT - 1 year ago

Precigen Announces Proposed $30 Million Public Offering of Common Stock

Precigen Strategically Prioritizes Portfolio to Focus on First Potential Gene Therapy Launch

Aug 6, 2024, 4:01 PM EDT - 1 year ago

Precigen Strategically Prioritizes Portfolio to Focus on First Potential Gene Therapy Launch

Precigen Appoints Phil Tennant as Chief Commercial Officer to Spearhead First Potential Gene Therapy Launch

Jul 23, 2024, 8:01 AM EDT - 1 year ago

Precigen Appoints Phil Tennant as Chief Commercial Officer to Spearhead First Potential Gene Therapy Launch

Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response

Jun 3, 2024, 9:30 AM EDT - 1 year ago

Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response

Precigen to Host a Webcast on June 3rd to Detail Pivotal Study Results of PRGN-2012 in Recurrent Respiratory Papillomatosis Presented at the 2024 ASCO Annual Meeting

May 23, 2024, 5:00 PM EDT - 1 year ago

Precigen to Host a Webcast on June 3rd to Detail Pivotal Study Results of PRGN-2012 in Recurrent Respiratory Papillomatosis Presented at the 2024 ASCO Annual Meeting

Precigen Reports First Quarter 2024 Financial Results and Business Updates

May 14, 2024, 4:05 PM EDT - 1 year ago

Precigen Reports First Quarter 2024 Financial Results and Business Updates

Precigen to Announce First Quarter 2024 Financial Results on May 14th and Host a Conference Call on June 3rd following the Late-breaking Oral Presentation for PRGN-2012 at the 2024 ASCO Annual Meeting

May 8, 2024, 4:05 PM EDT - 1 year ago

Precigen to Announce First Quarter 2024 Financial Results on May 14th and Host a Conference Call on June 3rd following the Late-breaking Oral Presentation for PRGN-2012 at the 2024 ASCO Annual Meeting

Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting

Apr 24, 2024, 10:20 AM EDT - 1 year ago

Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting

Actym Therapeutics Appoints Thomas Smart as CEO

Apr 24, 2024, 9:00 AM EDT - 1 year ago

Actym Therapeutics Appoints Thomas Smart as CEO

ANAB XOMA

Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th

Mar 28, 2024, 4:05 PM EDT - 1 year ago

Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th

Precigen, Inc. (PGEN) Q4 2023 Earnings Call Transcript

Mar 19, 2024, 8:49 PM EDT - 1 year ago

Precigen, Inc. (PGEN) Q4 2023 Earnings Call Transcript

Precigen Reports Full Year 2023 Financial Results and Business Updates

Mar 19, 2024, 4:05 PM EDT - 1 year ago

Precigen Reports Full Year 2023 Financial Results and Business Updates

Precigen to Participate in a Fireside Chat Hosted by Cantor Fitzgerald to Discuss PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis

Mar 12, 2024, 4:05 PM EDT - 1 year ago

Precigen to Participate in a Fireside Chat Hosted by Cantor Fitzgerald to Discuss PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis

Precigen to Announce Fourth Quarter and Full Year 2023 Financial Results on March 19th

Mar 5, 2024, 4:05 PM EST - 2 years ago

Precigen to Announce Fourth Quarter and Full Year 2023 Financial Results on March 19th

Precigen to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Feb 6, 2024, 4:05 PM EST - 2 years ago

Precigen to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Precigen: RRP Targeting With AdenoVerse Technology Platform

Jan 19, 2024, 7:39 PM EST - 2 years ago

Precigen: RRP Targeting With AdenoVerse Technology Platform

Inoboatguy
Inoboatguy Jan. 6 at 11:31 PM
$INO $PGEN is dog turd crap 💩 Scope surgery still needed during treatment, not counted in trial Pgen is 💩 INO is the far superior treatment 💪 winner
4 · Reply
M22
M22 Jan. 6 at 9:55 PM
$PGEN https://www.openpr.com/news/4334898/immunotherapy-drugs-market-to-reach-usd-872-64-billion-by-2033
0 · Reply
M22
M22 Jan. 6 at 9:48 PM
$PGEN https://www.bcbst.com/UpcomingMPs/Topics_12_31_25/Zopapogene%20Imadenovec-drba%20(Papzimeos)_pol.pdf
1 · Reply
M22
M22 Jan. 6 at 9:44 PM
$PGEN words getting out https://www.wdef.com/new-option-for-rare-hpv-disease/
0 · Reply
JFDI
JFDI Jan. 6 at 8:58 PM
$PGEN so sexy
0 · Reply
Champi2305
Champi2305 Jan. 6 at 8:10 PM
$PGEN
0 · Reply
INOVIO
INOVIO Jan. 6 at 7:47 PM
$INO $PGEN @iBio_GlaisterPIT One question before I answer you. Hypothetically, when INOVIO’s BLA for 3107 is FDA approved in ~10 months, what is the real difference between INOVIO at a ~$100M market cap and Precigen at ~$1.5B? Other than the medicines being different and patients having a choice, both would have FDA approval, correct? Do you think investors would look at INOVIO and say it’s massively undervalued or look at Precigen and ask why it’s valued 15X higher? This is a hypothetical question if they get their FDA approval. Please don’t respond with “FDA won’t approve it.” We’ve all heard that argument before.
1 · Reply
ivanhoff
ivanhoff Jan. 6 at 6:48 PM
$PGEN - speculative biotech with no profit and a tiny revenue, potentially setting up in a high-tight-flag setup.
0 · Reply
Champi2305
Champi2305 Jan. 6 at 6:41 PM
$PGEN $4,5 then $5
0 · Reply
iBio_GlaisterPIT
iBio_GlaisterPIT Jan. 6 at 6:11 PM
$INO $PGEN Some paid Inovio employees are trying to convince you the math that, as long as Precigen continues to rise, it’s somehow good for Inovio’s investors. My question is what math is that? It’s not mathematics as humans know it, so where does that math come from? Let’s look at JUST TODAY’S FACTS ALONE: Precigen - UP over 7% Inovio - Once again, down. Today only 2.5% Please do explain this Unicorn to us feeble-minded folks! Explain it like we only know 1+1=2. But give me a minute, going to make some popcorn, put on my hip-waders and put on my face shield so I don’t get splattered with how deep this shit’s gonna get!
1 · Reply
iBio_GlaisterPIT
iBio_GlaisterPIT Jan. 6 at 6:02 PM
$INO $PGEN
0 · Reply
RioesFather
RioesFather Jan. 6 at 5:57 PM
$INO $PGEN or is Precigen’s share price increase telling you Inovio is never getting approved? Keep buying those fake Inovio shares though buddy, aka Robert the rocketman
1 · Reply
INOVIO
INOVIO Jan. 6 at 5:37 PM
$INO $PGEN The higher PGEN goes, the better it is for INOVIO. With roughly 9 months until BLA approval, the valuation gap is hard to ignore. PGEN sits around a $1.5B market cap, while INOVIO is still near $100M. The setup speaks for itself. You do the math!
1 · Reply
StockDad0927
StockDad0927 Jan. 6 at 5:32 PM
$PGEN $6 soon
0 · Reply
Wacousta
Wacousta Jan. 5 at 10:45 PM
$PGEN FYI https://investors.precigen.com/news-releases/news-release-details/precigen-present-44th-annual-jp-morgan-healthcare-conference/
0 · Reply
Champi2305
Champi2305 Jan. 5 at 6:24 PM
$PGEN will be huge !
0 · Reply
Wacousta
Wacousta Jan. 5 at 5:49 PM
$PGEN
0 · Reply
M22
M22 Jan. 5 at 4:52 PM
$PGEN still adding…..
0 · Reply
M22
M22 Jan. 5 at 4:27 PM
$PGEN fishing for those stop losses
0 · Reply
M22
M22 Jan. 5 at 4:18 PM
$PGEN looks like the bears are back from holiday
1 · Reply
updownsides
updownsides Jan. 4 at 8:17 AM
$PGEN This is the Super Bowl of heath conferences. It should be a catalyst for Precigen. Especially if new information about uptake is presented that pleases the experts. "The 44th Annual J.P. Morgan Healthcare Conference (JPM 2026) is scheduled for January 12–15, 2026, in San Francisco, CA, primarily at the Westin St. Francis Hotel, serving as the industry's largest healthcare investment symposium for networking, deal-making, and exploring innovations across pharma, biotech, medtech, and digital health. This invitation-only event connects global leaders, investors, and innovators, with many major industry announcements timed to coincide with it, making it a key barometer for the year's healthcare trends."
2 · Reply
dsup
dsup Jan. 3 at 12:53 AM
$PGEN jan 15th. mark ur calendars 😎
1 · Reply